Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Teva is the largest generic pharmaceutical manufacturer in the world, with sales worth US$13.9 billion in 2009. The company is Israeli-owned and headquartered, although around 62% of revenues are gained in the USA.
In July 2005, Teva announced a merger with IVAX, one of the USA’s leading generic companies. The acquisition was completed in January 2006, in a deal worth some US$7.4 billion. The deal strengthened Teva’s position in the USA and Latin America.
In 2008, Teva announced it was acquiring the US generic firm, Bentley Pharmaceuticals, in a deal worth some US$360 million. Although based in the US, Bentley’s main business was in Spain, with additional operations in other parts of Europe.
In July 2008, Teva Pharmaceutical Industries announced plans to acquire Barr in a deal worth some US$7.46 billion. The deal completed in December 2008, creating a company that operates in over 60 countries and employs some 37,000 people. The acquisition drove Teva's North America revenues increase in 2009.
While the bulk of Teva’s revenues are derived from generics, the company has one major innovative product, Copaxone. This is a treatment for multiple sclerosis. Sales of Copaxone broke the US$1 billion mark in 2005, and were worth US$2.83 billion in 2009. A second innovative product, Azilect (rasagiline, Parkinson’s disease), was launched in 2006. Teva is also involved in research in other areas such as drug delivery and biosimilars.
In February 2010, the FDA accepted for filing Teva's Biologics Licence Application for XM02, the firm's G-CSF product. Teva submitted its BLA in November 2009, underscoring the firm's scepticism that Congress would be able to create a regulatory pathway for biosimilars.
In March 2010, Teva announced that it was to acquire ratiopharm for an enterprise value of 3.625 billion euros (US$4.9 billion). The deal will position Teva as the leading generics player in Europe, and cement its position as the largest generics firm in the world. The acquisition completed on 10th August 2010.